Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics CEO Nello Mainolfi reported a mix of option exercises and share sales in the company’s stock. On July 1, 2026, he exercised stock options for 80,000 shares of common stock at an exercise price of $2.08 per share, converting a derivative position into regular shares.
That same day, he sold 80,000 shares of common stock in five open-market transactions at weighted average prices ranging from about $112.28 to $116.63 per share. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and notes that he continues to hold a substantial direct equity stake in Kymera.
Kymera Therapeutics director-related entities reported an amended open-market sale of Kymera common stock. Entities associated with Bruce Booth, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a total of 76,650 shares of Kymera Therapeutics, Inc. on June 29, 2026.
The trades were executed as open-market sales at weighted average prices within ranges from about $105.02 to $111.63 per share under a Rule 10b5-1 trading plan adopted on December 11, 2025. The filing is an amendment that corrects previously misreported numbers of shares disposed and owned following the transactions. Booth reports these holdings indirectly through the Atlas funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.
KYR Medicines, Inc. (KYMR) reported a Section 144 notice indicating an intended sale of 80,000 shares of Common Stock on 07/01/2026 arising from an exercise of stock options with cash as the payment method. The filing also records a prior sale of 30,000 shares on 04/29/2026.
The filing lists an aggregate dollar figure of $9,143,200.00 and a share count of 82,257,588 tied to 07/01/2026. The notice names Nello Mainolfi in the recent sale record.
Noah Goodman reported insider sales of Common Stock via Rule 10b5-1 plans. The filing lists multiple dispositions between 04/09/2026 and 06/25/2026, including representative transactions of 5,764 shares for $500,582.20, 5,000 shares for $570,000.00, and other 10b5-1 sales. The report identifies the securities as Restricted Stock Units converted to Common and sold under pre-arranged plans.
Kymera Therapeutics director Bruce Booth reported indirect open-market sales of a total of 31,283 shares of Kymera common stock on June 29, 2026. The trades, executed at weighted-average prices between about $108 and $111 per share, were made under a pre-arranged Rule 10b5-1 trading plan by Atlas Venture funds that hold the shares, for which Booth disclaims beneficial ownership beyond any pecuniary interest.
Kymera Therapeutics, Inc. director Bruce Booth reported that investment entities associated with him, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a combined 513,245 shares of Kymera common stock in open-market transactions.
The sales occurred on June 26 and June 29, 2026 at weighted-average prices such as $118.66 and $105.78 per share, executed under a pre-established Rule 10b5-1 trading plan. The filing shows that these entities continue to hold large indirect positions, including reported post-transaction holdings of 466,077 and 2,603,048 shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice to sell 61,378 shares of Common Stock tied to the exercise of stock options.
The filing also lists 15,731 Restricted Stock Units with an earlier grant date of 03/01/2025. The sales are presented on the form with an effective/filing date of 06/30/2026 and the securities are listed for trading on NASDAQ.
KYMR reported notices of proposed sale of Common Stock by multiple selling holders under Rule 144. The excerpt lists specific sale notices and recent transactions by holders such as Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., and individual holders including Bruce Booth.
The filings show proposed or recent sales on dates including 04/15/2026, 04/22/2026, and multiple dates in June 2026, with per‑transaction share counts and dollar amounts reported for each selling holder.
The issuer listed Common Stock for sale under Form 144 with Nasdaq listed securities; the notice is dated 06/29/2026. The excerpt lists multiple proposed sales by holders including Atlas Venture Funds and Bruce Booth with trade dates from 04/15/2026 through 06/26/2026.
Funds affiliated with BVF Partners reported significant stock sales in Kymera Therapeutics, Inc. common shares. On 2026-06-26, Section 13(d) group members filed a joint Form 4 showing open-market sales totaling 1,630,658 shares of Kymera common stock at $106.50 per share, split between direct and indirect holdings.
The filing also lists a series of vested and time-based stock options, with exercise prices ranging from $14.18 to $99.87 per share and expirations from 2030 to 2036, held indirectly through BVF-managed entities. In addition, the group retains several pre-funded warrants exercisable at $0.0001 per share that, according to the disclosure, are exercisable at any time and do not expire. Collectively, these derivatives indicate that BVF-affiliated vehicles remain substantial economic holders of Kymera beyond the reported common share sales.